Compare MGTX & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGTX | SLBT |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 942.1M |
| IPO Year | 2018 | 2025 |
| Metric | MGTX | SLBT |
|---|---|---|
| Price | $10.89 | $1.57 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $27.75 | N/A |
| AVG Volume (30 Days) | ★ 932.9K | 101.3K |
| Earning Date | 11-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.02 | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $81,391,000.00 | N/A |
| Revenue This Year | $314.19 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.40 | ★ N/A |
| Revenue Growth | ★ 144.57 | N/A |
| 52 Week Low | $6.62 | $1.42 |
| 52 Week High | $15.35 | $6.25 |
| Indicator | MGTX | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 31.37 | 33.81 |
| Support Level | $8.84 | $1.42 |
| Resistance Level | $11.85 | $3.36 |
| Average True Range (ATR) | 0.58 | 0.17 |
| MACD | -0.18 | 0.01 |
| Stochastic Oscillator | 13.29 | 21.74 |
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.